Alexander’s Library

The search for the elixir of youth — what the record says, and how strongly. Double-click any word for an instant dictionary or scientific synopsis.

Library / Natural & Life Sciences / Medicine, Health & Longevity / Reproductive Medicine & Human Fertility / Advanced Maternal Age & Pregnancy After 40

Fetal Growth Restriction and Congenital Malformations

Risk assessment, ultrasound biometry, Doppler hemodynamics, and incidence of structural non-chromosomal congenital anomalies in pregnancies at elevated maternal age.

136 sources ↓Last researched 2026-10-16
Hierarchy:
Natural & Life SciencesMedicine, Health & LongevityReproductive Medicine & Human FertilityAdvanced Maternal Age & Pregnancy After 40Fetal Growth Restriction and Congenital MalformationsCongenital AbnormalitiesFetal Growth RetardationPlacenta Diseases
+ Associated nodes:
Clinical Efficacy & Obstetric Outcomes (intersects) Clinical Nutrition and Assisted Reproductive Technology Outcomes (intersects) Hyaluronan Biochemistry & Endometrial Adhesion Mechanisms (intersects) Impact on Endometrial Receptivity and Fecundity (intersects) Micronutrient Supplementation in Ovarian Aging (intersects) Reproductive Nutrition, Dietary Patterns & Ovulatory Function (intersects) Ovarian Refractoriness and Endocrine Environment (intersects) Ovarian Reserve and Primordial Follicle Activation (intersects) Patient Stratification & Indications (intersects) Perinatal Safety & Neonatal Outcomes (intersects) Perinatal Safety and Maternal Epigenetic Outcomes (intersects) Micronutrient, Antioxidant & Mitochondrial Fertility Supplementation (intersects)
State of the Field Monograph · AI Research Synthesis5 min read · 136 sources · 25 graded findingsPeak certainty: T1

State of the Field: Fetal Growth Restriction and Congenital Malformations

Risk assessment, ultrasound biometry, Doppler hemodynamics, and incidence of structural non-chromosomal congenital anomalies in pregnancies at elevated maternal age. Grounded synthesis across 136 primary sources and 25 graded findings within Reproductive Medicine & Human Fertility → Advanced Maternal Age & Pregnancy After 40.

Synopsis · Executive Overview

Advanced maternal age (≥35 years) is independently associated with an elevated risk of stillbirth (OR 1.75, 95% CI 1.62-1.89), fetal growth restriction (FGR), and non-chromosomal congenital anomalies (OR 1.09 to 1.24). FGR is diagnosed via weight below the 10th percentile or severe status below the 3rd percentile, coupled with abnormal biometry, uterine/umbilical artery Doppler indices, and cerebroplacental ratios. Very advanced age (≥45 or ≥50 years) further increases risks of preterm birth (OR 1.96), fetal loss (OR 2.60), and placental abnormalities. Low-dose aspirin (≥100 mg) started by 16 weeks offers modest risk reduction for small-for-gestational-age births in high-risk groups, while interventions like sildenafil have shown no clinical benefit in severe early-onset FGR. Combining estimated fetal weight with biomarkers like the sFlt-1/PlGF ratio improves short-term adverse outcome prediction.

Section I · Primary Literature & Evidence Synthesis

What the Peer-Reviewed Record Establishes

The primary research record in Fetal Growth Restriction and Congenital Malformations is stratified by study design so that meta-analyses and replicated randomised controlled trials (T1–T2) carry greater epistemic weight than observational cohorts (T3–T4) or preclinical laboratory work (T5). Leading graded findings establish the core empirical baseline: [T1] Small for gestational age (SGA) is defined as weight below the 10th percentile, while severe SGA is defined as weight below the 3rd percentile, with fetal growth restriction (FGR) identified by abnormal growth trajectory or Doppler findings. [97] [T1] Low-dose aspirin (≥100 mg) started at or before 16 weeks of gestation modestly reduces the risk of small-for-gestational-age birth in high-risk pregnancies. [80]

Further clinical and mechanistic stratification across the literature demonstrates: [T1] Very advanced maternal age (>= 45 years) is associated with an increased likelihood of fetal loss (OR 2.60) and preterm birth (OR 1.96) compared to younger mothers. [83] [T1] Advanced maternal age (≥35 years) is associated with an increased risk of stillbirth (OR 1.75, 95% CI 1.62-1.89) and fetal growth restriction. [85][86]

Section II · Mechanisms, Interventions & Subgroup Calibration

Comparative Evaluation of Levers & Theoretical Models

When evaluated as a quantitative decision and mechanism ledger, the best-supported interventions and frameworks in Fetal Growth Restriction and Congenital Malformations are: Low-Dose Aspirin (≥100 mg) (Supported — Modest reduction in small-for-gestational-age birth incidence; landmark evidence: High-risk pregnancy trials and systematic reviews: Supported for high-risk clinical profiles; timing before 16 weeks is critical for optimal trophoblastic invasion.); sFlt-1/PlGF Ratio & Biometry Screening (Targeted — Achieved an AUC of 0.75 for predicting short-term adverse perinatal outcomes; landmark evidence: Cohort studies of SGA/FGR pregnancies (n=440): Targeted clinical utility for refining surveillance intervals in suspected placental dysfunction.).

By contrast, interventions and hypotheses that remain experimental, subgroup-restricted, or unsupported by randomised endpoints include: Sildenafil Therapy (Not supported — Ineffective in prolonging pregnancy or improving perinatal outcomes; Not supported by trial evidence; should not be used as standard management for early-onset FGR.).

Within the Tree of Knowledge, this field branches into 3 specialised sub-disciplines: Congenital Abnormalities (Incidence and etiology of structural, non-chromosomal anomalies involving cardiovascular, musculoskeletal, and central nervous systems in relation to maternal age); Fetal Growth Retardation (Pathophysiology and diagnostic criteria for restricted fetal growth, focusing on the distinction between constitutionally small and pathologically restricted fetuses); Placenta Diseases (Investigation of placental insufficiency, ischemic placental disease, and vascular remodeling as drivers of growth restriction in older maternal cohorts).

Section III · Historical Trajectory & Contested Frontiers

Evolution of the Field, Open Debates & Active Trials

Chronologically, the field evolved through key inflection points: in 2016, Delphi Consensus on FGR Definition (An international panel established specific ultrasound and Doppler criteria to define and differentiate early and late fetal growth restriction); in 2018, STRIDER Trial Results (Evidence from a multicenter RCT demonstrated that sildenafil does not improve outcomes for severe early-onset FGR); in 2019, IRIS study results (Demonstrated that routine third-trimester ultrasound does not reduce adverse perinatal outcomes in low-risk singleton pregnancies).

Active scientific debates and unresolved methodological tensions centre on: Melatonin supplementation claims for IVF outcomes in women over 38 lack robust, large-scale RCT validation and currently reflect commercial overreach. (commercial hype) The exact magnitude of increased non-chromosomal congenital anomaly risk associated strictly with advanced maternal age varies across observational databases due to confounding by ART use and parity. (contested)

Section IV · Evidentiary Gaps & Research Frontiers

Open Questions & Priorities for the Next Research Sweep

Methodological priorities and open empirical questions queued for the next research sweep across Fetal Growth Restriction and Congenital Malformations focus on resolving subgroup effect sizes, causal mechanisms, and long-term outcomes:

  • What is the independent contribution of paternal age versus maternal age to de novo structural congenital anomalies?
  • Can targeted early-third-trimester biomarker and Doppler screening protocols meaningfully reduce stillbirth rates in advanced maternal age cohorts?
  • What are the precise molecular pathways linking advanced maternal age placental dysfunction to altered amino acid transport and FGR?
  • Multi-center prospective trials evaluating combined angiogenic marker thresholds (sFlt-1/PlGF) for timing delivery in late-preterm FGR.
  • Epigenetic and transcriptomic analyses of advanced maternal age placentas to isolate age-driven pathways from ART-induced artifacts.
  • Refined prediction algorithms incorporating paternal age metrics alongside maternal biometry for congenital malformation risk.

Evidence Hierarchy (Graded Claims)

  • T1Synthesis of trials
    5 (20%)
  • T2Randomised trial
    0 (0%)
  • T3Observational, large
    13 (52%)
  • T4Observational, small or case-based
    2 (8%)
  • T5Preclinical or mechanistic
    1 (4%)
  • T6Opinion, news or unverified
    4 (16%)
17 settled6 debated2 contested / frontier

Study Designs in Indexed Literature

  • Meta-analyses, Systematic Reviews & Guidelines16 (12%)
  • Randomised Controlled Trials (RCTs)7 (5%)
  • Prospective Cohorts & Clinical Registries27 (20%)
  • Observational & Clinical Case Series3 (2%)
  • Preclinical, Cellular & Computational Models4 (3%)
  • Primary Literature & Archive Records79 (58%)

Publication Timeline Velocity

Fig. 1 — Field Evidence Architecture & Publication Trajectory. Distribution of methodological study designs (136 indexed publications) and 25 extracted claims graded from T1 (meta-analyses and guidelines) to T6.

Epistemic Verdict Distribution Across Evaluated Levers & Mechanisms (4)

Supported1 lever (25%)
Targeted1 lever (25%)
Not supported1 lever (25%)
Case by case1 lever (25%)
Fig. 2 — Intervention & Mechanism Epistemic Calibration. Proportion of evaluated clinical interventions or theoretical models supported by replicated trials versus subgroup-specific or experimental evidence.
Primary Citations & Landmark Studies

Key Studies Anchoring This Monograph

Synthesis & Conclusions

State of the Field Conclusions

Taken together, the evidence record in Fetal Growth Restriction and Congenital Malformations (136 primary sources, 25 graded claims, highest certainty T1 — Synthesis of trials) separates replicated high-tier findings from early-stage hypotheses. The most robust actionable levers supported by current evidence are Low-Dose Aspirin (≥100 mg) (Modest reduction in small-for-gestational-age birth incidence), sFlt-1/PlGF Ratio & Biometry Screening (Achieved an AUC of 0.75 for predicting short-term adverse perinatal outcomes). The 6 open research priorities detailed above guide the next autonomous literature and clinical trial sweep.

Key Quantitative Takeaways

  • OR 1.75: Stillbirth risk in advanced maternal age (≥35 years) vs younger cohorts (Advanced Maternal Age Meta-Analysis, 2017).
  • OR 2.60: Fetal loss odds in very advanced maternal age (≥45 years) (Population Cohort Data, 2018).
  • Low-Dose Aspirin (≥100 mg) [Supported]: Modest reduction in small-for-gestational-age birth incidence — Supported for high-risk clinical profiles; timing before 16 weeks is critical for optimal trophoblastic invasion.
  • sFlt-1/PlGF Ratio & Biometry Screening [Targeted]: Achieved an AUC of 0.75 for predicting short-term adverse perinatal outcomes — Targeted clinical utility for refining surveillance intervals in suspected placental dysfunction.
  • Open frontier in Fetal Growth Restriction and Congenital Malformations: What is the independent contribution of paternal age versus maternal age to de novo structural congenital anomalies?
OR 1.75

Stillbirth risk in advanced maternal age (≥35 years) vs younger cohorts

Advanced Maternal Age Meta-Analysis, 2017

OR 2.60

Fetal loss odds in very advanced maternal age (≥45 years)

Population Cohort Data, 2018

OR 1.09–1.24

Elevated risk of congenital anomalies in pregnancies at ≥35 years

Epidemiological Studies, 2016-2022

Where each lever applies

A graded decision ledger of interventions across clinical subgroups. Each row names its best landmark evidence, measured effect, clinical reading, and epistemic verdict.

Supported: RCT live-birth gainTargeted: specific subgroupGuideline: clinical consensusWeak: inconsistent/unproven gainNot supported: RCTs show no gainTrial: human trial in progressLab: preclinical / cell dish

Prevention & First Trimester

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
Low-Dose Aspirin (≥100 mg)

Initiation at or before 16 weeks gestation to modify placental perfusion and reduce SGA/pre-eclampsia risk.

High-risk pregnancy trials and systematic reviews

Effect: Modest reduction in small-for-gestational-age birth incidence

Clinical reading: Supported for high-risk clinical profiles; timing before 16 weeks is critical for optimal trophoblastic invasion.

Supported

Risk Stratification

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
sFlt-1/PlGF Ratio & Biometry Screening

Combining angiogenic biomarkers with estimated fetal weight and umbilicocerebral ratios.

Cohort studies of SGA/FGR pregnancies (n=440)

Effect: Achieved an AUC of 0.75 for predicting short-term adverse perinatal outcomes

Clinical reading: Targeted clinical utility for refining surveillance intervals in suspected placental dysfunction.

Targeted

Therapeutic Intervention

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
Sildenafil Therapy

Phosphodiesterase-5 inhibitor intended to promote vasodilation and improve uteroplacental blood flow.

Randomized controlled trials in severe early-onset FGR (2018)

Effect: Ineffective in prolonging pregnancy or improving perinatal outcomes

Clinical reading: Not supported by trial evidence; should not be used as standard management for early-onset FGR.

Not supported

Surveillance

Lever & MechanismBest Landmark EvidenceMeasured Effect & Clinical ReadingVerdict
Routine Third-Trimester Ultrasound Screening

Universal ultrasound biometry scans performed in low-risk or advanced maternal age pregnancies.

Clinical trials and population screening studies

Effect: Increases detection of small-for-gestational-age fetuses without proving reduction in severe perinatal morbidity in low-risk groups

Clinical reading: Guideline or case-by-case evaluation warranted based on maternal age and risk stratification.

Case by case

Questions for specialist consultations

High-yield clinical and laboratory inquiries directly derived from the evidence record.

  1. What is our specific surveillance protocol for fetal growth restriction given maternal age and uterine artery Doppler indices?
  2. Are we incorporating first-trimester screening biomarkers (like PAPP-A) and sFlt-1/PlGF ratios to stratify placental insufficiency risk?
  3. What are the local institutional guidelines regarding timing and delivery thresholds for late preterm versus term advanced maternal age pregnancies complicated by borderline biometry?
  4. Has low-dose aspirin been initiated prior to 16 weeks gestation?

Queued for next research sweep

Frontier clinical trials, emerging biology, and targeted subgroup outcomes tracked by the autonomous research worker.

  • Multi-center prospective trials evaluating combined angiogenic marker thresholds (sFlt-1/PlGF) for timing delivery in late-preterm FGR.
  • Epigenetic and transcriptomic analyses of advanced maternal age placentas to isolate age-driven pathways from ART-induced artifacts.
  • Refined prediction algorithms incorporating paternal age metrics alongside maternal biometry for congenital malformation risk.
Historical timeline (3 milestones, 2016–2019)
  1. 2016

    Delphi Consensus on FGR Definition

    An international panel established specific ultrasound and Doppler criteria to define and differentiate early and late fetal growth restriction.

  2. 2018

    STRIDER Trial Results

    Evidence from a multicenter RCT demonstrated that sildenafil does not improve outcomes for severe early-onset FGR.

  3. 2019

    IRIS study results

    Demonstrated that routine third-trimester ultrasound does not reduce adverse perinatal outcomes in low-risk singleton pregnancies.

Evidence by study design (25 findings across T1–T6)

Strongest support first. The bar beside each finding shows its grade.

Synthesis of trials

  1. #1 Small for gestational age (SGA) is defined as weight below the 10th percentile, while severe SGA is defined as weight below the 3rd percentile, with fetal growth restriction (FGR) identified by abnormal growth trajectory or Doppler findings.

    Fetal growth restriction and intra-uterine growth restriction: guide… (2015)

    Clinical definitions are necessary for consistent diagnosis and monitoring of growth restriction.

  2. #2 Low-dose aspirin (≥100 mg) started at or before 16 weeks of gestation modestly reduces the risk of small-for-gestational-age birth in high-risk pregnancies.

    The role of aspirin, heparin, and other interventions in the prevent… (2018)

    This is a key preventive strategy recommended in current guidelines.

  3. #3 Very advanced maternal age (>= 45 years) is associated with an increased likelihood of fetal loss (OR 2.60) and preterm birth (OR 1.96) compared to younger mothers.

    The Effect of Very Advanced Maternal Age on Maternal and Neonatal Ou… (2018)

    Systematic review highlights significantly elevated risks for adverse perinatal outcomes at very advanced maternal age.

  4. #4 Advanced maternal age (≥35 years) is associated with an increased risk of stillbirth (OR 1.75, 95% CI 1.62-1.89) and fetal growth restriction.

    Advanced maternal age and adverse pregnancy outcomes: A systematic r… (2017); Placental Dysfunction Underlies Increased Risk of Fetal Growth Restr… (2017)

    Meta-analysis indicates that the risk of adverse outcomes like stillbirth and FGR in older mothers is not entirely explained by co-morbidities or assisted reproductive technology.

  5. #5 Women in the advanced maternal age group (≥35 years) show increased odds of non-chromosomal congenital anomalies (OR 1.09, 95% CI 1.01-1.17) compared to the 20-34 year age group.

    DebatedCongenital anomalies and maternal age: A systematic review and meta‐… (2022); Epidemiology of Birth Defects Based on a Birth Defect Surveillance S… (2016)

    Evidence for non-chromosomal anomaly risk is rated as very low quality due to potential unadjusted confounders.

Observational, large

  1. #6 Sildenafil is ineffective in prolonging pregnancy or improving perinatal outcomes in severe early-onset fetal growth restriction.

    Maternal sildenafil for severe fetal growth restriction (STRIDER): a… (2018)

    This RCT indicates that common off-label pharmacological interventions for FGR do not provide clinical benefit.

  2. #7 Routine third-trimester ultrasound screening in low-risk pregnancies increases detection of small-for-gestational-age fetuses but does not reduce severe perinatal morbidity.

    DebatedEffectiveness of routine third trimester ultrasonography to reduce a… (2019)

    High-quality randomized data suggests routine scans do not improve clinical outcomes despite better diagnosis rates.

  3. #8 Among 12,189 advanced maternal age pregnancies, those with polycystic ovary syndrome (364 cases) showed reduced second- and third-trimester fetal biometry Z-scores, which were modified and mitigated by assisted reproductive technology conception.

    Fetal growth in PCOS pregnancies: dynamic evidence of restriction an… (2026)

    Links maternal endocrine conditions and ART modulation to fetal growth trajectories in advanced maternal age cohorts.

  4. #9 In nulliparous women, the combination of ultrasonically suspected small-for-gestational-age infants and an elevated sFLT1/PlGF ratio (>85th percentile) at 28 or 36 weeks demonstrates a higher predictive value for adverse perinatal outcomes than ultrasound alone.

    DebatedScreening for fetal growth restriction using ultrasound and the sFLT… (2018)

    While promising, the utility of universal screening for FGR using these biomarkers is still under investigation for general clinical implementation.

  5. #10 In a cohort of 440 singleton small-for-gestational-age pregnancies, a prediction model combining estimated fetal weight, sFlt-1/PlGF ratio, and umbilicocerebral ratio achieved an AUC of 0.75 for short-term adverse perinatal outcome.

    Predictive value of fetal Doppler velocimetry, fetal growth trajecto… (2025)

    Establishes a predictive multi-marker model for adverse outcomes in growth-restricted fetuses.

  6. #11 Severe early-onset fetal growth restriction outcomes, including neonatal death, can be predicted using a combination of fetal weight z-score and umbilical artery Doppler velocimetry.

    Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at d… (2023)

    Accurate prediction models are critical for clinical counseling in high-risk pregnancies.

  7. #12 In pregnancies presenting with reduced fetal movements, poor perinatal outcomes are closely tied to placental dysfunction indicators, including abnormal fetal heart rate traces, diastolic blood pressure, and estimated fetal weight centiles.

    Predictors of poor perinatal outcome following maternal perception o… (2012)

    Identifies independent predictive biometric and Doppler-related risk factors for adverse outcomes.

  8. #13 Combining first-trimester maternal history, uterine artery Doppler pulsatility index, and low PAPP-A levels improves the prediction of small-for-gestational-age infants and pre-eclampsia.

    Screening for pre-eclampsia and fetal growth restriction by uterine … (2007)

    Shows multi-marker screening effectiveness at 11-14 weeks gestation.

  9. #14 Advanced paternal age is associated with an increased prevalence of malformations of the extremities, multiple system syndromes, and Down's syndrome, such as an adjusted hazard ratio of 3.20 for multiple system syndromes at ages >= 50.

    DebatedPaternal age and congenital malformations (2005)

    Population cohort study shows specific structural malformations increase with paternal age.

  10. #15 In fetal growth-restricted pregnancies, abnormal venous Doppler findings (ductus venosus or inferior vena cava) are significantly more predictive of adverse perinatal outcomes, including fetal death and acidemia, compared to isolated umbilical artery abnormalities.

    Relationship between arterial and venous Doppler and perinatal outco… (2000)

    Doppler hemodynamic assessment is a cornerstone of surveillance for established FGR.

  11. #16 After controlling for maternal age, parity, and ethnicity, IVF conceptions do not show a statistically significant increase in overall congenital malformations compared to natural conceptions (OR 1.03).

    Congenital malformations in 4224 children conceived after IVF (2002)

    Demonstrates that baseline maternal characteristics rather than the IVF technique largely account for crude malformation rate differences.

  12. #17 Fetal growth restriction is associated with maternal cardiovascular changes, specifically a low-output high-resistance state and asymptomatic diastolic dysfunction.

    Maternal Cardiovascular Impairment in Pregnancies Complicated by Sev… (2012)

    Maternal health assessment provides insight into the long-term sequelae of growth-restricted pregnancies.

  13. #18 Melatonin supplementation (2 mg daily) in women aged ≥38 years undergoing IVF is associated with significantly higher clinical pregnancy and live birth rates compared to control groups.

    Marketed ahead of evidenceMelatonin supplementation attenuates cuproptosis and ferroptosis in … (2024)

    While initial findings suggest potential benefits for IVF outcomes in AMA, this is a single cohort study requiring validation before clinical adoption.

Observational, small or case-based

  1. #19 In a prospective cohort of 86 singleton small-for-gestational-age pregnancies, maternal cardiac output and stroke volume were decreased while peripheral vascular resistance was increased.

    Maternal hemodynamics, fetal biometry and Doppler indices in pregnan… (2018)

    Demonstrates specific maternal hemodynamic alterations linked to fetal growth restriction.

  2. #20 Women over 50 years undergoing assisted reproductive technology experience higher rates of placental abnormalities (3.92 times) and low birth weight (1.67 times) compared to younger women.

    High-Risk Outcomes in In Vitro Fertilization Pregnancies for Women o… (2025)

    Very advanced maternal age is a high-risk demographic for pregnancy complications involving placental dysfunction.

Preclinical or mechanistic

  1. #21 Advanced maternal age induces sex-specific placental phenotypic changes, such as altered endocrine zone size and glucocorticoid metabolism, in rat models.

    Frontier / fringeAdvanced maternal age compromises fetal growth and induces sex-speci… (2019)

    While mechanistic in rats, it highlights potential biological pathways for fetal growth restriction observed in human aging.

Opinion, news or unverified

  1. #22 Fetal growth restriction (FGR) is defined by a combination of biometric parameters and Doppler indices, including the umbilical artery pulsatility index and cerebroplacental ratio.

    Clinical Opinion: The diagnosis and management of suspected fetal gr… (2022); Diagnosis and surveillance of late-onset fetal growth restriction. (2018); Consensus definition of fetal growth restriction: a Delphi procedure (2016)

    Standardization of FGR diagnosis is critical for clinical management and surveillance, distinguishing between early (<32 weeks) and late (>32 weeks) onset.

  2. #23 Advanced maternal age (≥40 years) is independently associated with increased risks of preeclampsia, fetal growth restriction (FGR), and other adverse perinatal outcomes, while assisted reproductive technologies (ART) may have additive or synergistic effects on these risks.

    Advanced maternal age and assisted reproductive technologies: outcom… (2026); The updated understanding of advanced maternal age (2023); Placental Dysfunction in Assisted Reproductive Pregnancies: Perinata… (2022)

    AMA and ART are recognized clinical risk factors for placental dysfunction leading to FGR.

  3. #24 Positive secular trends in health and education may partially counterbalance the individual risks associated with advanced maternal age.

    DebatedAdvanced Maternal Age and Offspring Outcomes: Reproductive Aging and… (2016)

    This highlights the influence of societal and environmental factors on offspring outcomes beyond maternal age alone.

  4. #25 Low levels of maternal serum Vitamin D-binding protein (VDBP) are associated with adverse outcomes including fetal growth restriction.

    DebatedVitamin D-Binding Protein in Pregnancy and Reproductive Health (2020)

    The relationship between VDBP levels and specific obstetric outcomes requires further validation with more accurate assays.

Where the record disagrees (2 controversies)

  • Melatonin supplementation claims for IVF outcomes in women over 38 lack robust, large-scale RCT validation and currently reflect commercial overreach.

    Findings #18

  • The exact magnitude of increased non-chromosomal congenital anomaly risk associated strictly with advanced maternal age varies across observational databases due to confounding by ART use and parity.

    Findings #5

Node lineage & crossover disciplines

Parent lineage, active node, direct child sub-branches, and associated crossover disciplines across the Tree of Knowledge.

Hierarchy:
Natural & Life SciencesMedicine, Health & LongevityReproductive Medicine & Human FertilityAdvanced Maternal Age & Pregnancy After 40Fetal Growth Restriction and Congenital MalformationsCongenital AbnormalitiesFetal Growth RetardationPlacenta Diseases
+ Associated nodes:
Clinical Efficacy & Obstetric Outcomes (intersects) Clinical Nutrition and Assisted Reproductive Technology Outcomes (intersects) Hyaluronan Biochemistry & Endometrial Adhesion Mechanisms (intersects) Impact on Endometrial Receptivity and Fecundity (intersects) Micronutrient Supplementation in Ovarian Aging (intersects) Reproductive Nutrition, Dietary Patterns & Ovulatory Function (intersects) Ovarian Refractoriness and Endocrine Environment (intersects) Ovarian Reserve and Primordial Follicle Activation (intersects) Patient Stratification & Indications (intersects) Perinatal Safety & Neonatal Outcomes (intersects) Perinatal Safety and Maternal Epigenetic Outcomes (intersects) Micronutrient, Antioxidant & Mitochondrial Fertility Supplementation (intersects)

Branches

  • Congenital Abnormalities Incidence and etiology of structural, non-chromosomal anomalies involving cardiovascular, musculoskeletal, and central nervous systems in relation to maternal age.
  • Fetal Growth Retardation Pathophysiology and diagnostic criteria for restricted fetal growth, focusing on the distinction between constitutionally small and pathologically restricted fetuses.
  • Placenta Diseases Investigation of placental insufficiency, ischemic placental disease, and vascular remodeling as drivers of growth restriction in older maternal cohorts.
AI Tree OrganiserExpand Fetal Growth Restriction and Congenital Malformations

Branches are never named or placed manually. Ask any scientific question — AI decomposes multi-part inquiries into one, two, three, or more canonical sub-branches and places each under its proper discipline.

Public archive: please keep questions to general scientific concepts (no names, dates of birth, or personal health identifiers). Privacy & copyright.

Auto-classifies taxonomy & cross-links
Primary indexed sources (136)

Primary scientific literature, systematic reviews, and clinical trial registrations indexed for this branch.

  1. Advanced maternal age and assisted reproductive technologies: outcomes, genomics, and real-world evidence — Cristina Méndez‐Vidal, M. Fernández-Sánchez, Marta Domínguez-Moreno et al. Frontiers in Reproductive Health, 2026, unknown, 6 citations · DOI: 10.3389/frph.2026.1787867
  2. Inflammation at the Maternal–Fetal Interface: Mechanisms Linking Maternal–Fetal Immunity to Preeclampsia and Fetal Growth Restriction — Maestre N., Roberto Zapata, Mariana Devia et al. International Journal of Molecular Sciences, 2026, unknown, 6 citations · DOI: 10.3390/ijms27093954
  3. Consensus and controversies of international guidelines for the diagnosis, surveillance, and management of fetal growth restriction: an updated comparison. — Di Mascio D, Chauhan SP, Ghi T et al. American journal of obstetrics and gynecology, 2026, guideline, 1 citations · DOI: 10.1016/j.ajog.2026.04.010
  4. Fetal growth in PCOS pregnancies: dynamic evidence of restriction and the modifying role of ART. — Xu H, Liu Y, Bian X et al. Frontiers in medicine, 2026, cohort · DOI: 10.3389/fmed.2026.1857905
  5. Ultrasound Assessment of the Fetal Pancreas in Normal and Abnormal Pregnancies: A Narrative Review. — Golbasi H Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2026, systematic review · DOI: 10.1002/jum.70357
  6. Fetal Adrenal Gland Ultrasound Parameters in Pregnancies with Fetal Growth Restriction Defined by Delphi Criteria: A Prospective Single-Center Case-Control Study. — Özalp E, Akbulut ÖV, Sucu S et al. Journal of clinical medicine, 2026 · DOI: 10.3390/jcm15083082
  7. Maternal and fetal outcomes with increasing maternal age during pregnancy: a hospital-based study — Anjana Mavelil, Neetha Nandan International Journal of Reproduction Contraception Obstetrics and Gynecology, 2026, cohort · DOI: 10.18203/2320-1770.ijrcog20260192
  8. The impact of maternal age on congenital heart defects and their severity in Down syndrome — Nurdan Erol, Çiğdem Erol, Abdullah Alpınar et al. Ümraniye Pediatri Dergisi - Journal of Umraniye Pediatrics, 2026 · DOI: 10.14744/upd.2026.83007
  9. Conventional statistical and machine learning-based prediction of neonatal outcomes in late-onset fetal growth restriction. — Kapudere B, Aydın R, Aydın Ö et al. Journal of perinatal medicine, 2026 · DOI: 10.1515/jpm-2026-0344
  10. Placental apelin expression is low in early-onset fetal growth restriction but there is no association between maternal circulating apelin and pregnancy outcome. — Braun N, Bethell K, Chaloner L et al. Placenta, 2026 · DOI: 10.1016/j.placenta.2026.04.023
  11. PFAS exposure and reproductive dysfunction: implications for outcomes in assisted reproductive technologies — Xin Shu, Wenjie Zhou, Tao Zhang et al. Frontiers in Endocrinology, 2026 · DOI: 10.3389/fendo.2026.1808266
  12. Global Burden of Meconium-Stained Amniotic Fluid: A Systematic Review and Meta-Analysis of Prevalence With Descriptive Synthesis of Determinants. — Tabrizian S, Mirzarahimi T, Mirghafourvand M et al. Health science reports, 2026 · DOI: 10.1002/hsr2.73069
  13. Therapeutic Synergy of Probiotic Augmented Conventional Antidiabetic Pharmacotherapy in Gestational Diabetes Mellitus Riphah International University, 2026, rct
  14. Association of pre-pregnancy abnormal glucose metabolism and insulin resistance with assisted reproductive technology outcomes and pregnancy complications in women with PCOS: a retrospective propensity score matching study — Xiangting Shen, Jihong Zou, Junxia Song et al. BMC Pregnancy and Childbirth, 2026 · DOI: 10.1186/s12884-026-09449-8
  15. Association of Fetal Intrahepatic Umbilical-Portal Anastomosis Type with Late-Onset Fetal Growth Restriction and Neonatal Outcomes. — Çanga K, Ağaoğlu RT, Akbulut ÖV et al. Diagnostics (Basel, Switzerland), 2026 · DOI: 10.3390/diagnostics16142253
  16. Nutrition Counseling, Diet Quality, and Advanced Glycation End Products in Gestational Diabetes Istanbul Saglik Bilimleri University, 2026, rct
  17. Maternal serum neuroserpin in late-onset fetal growth restriction: a prospective case-control study. — Hızlı B, Kaya M, Kurt A et al. European journal of obstetrics, gynecology, and reproductive biology, 2026 · DOI: 10.1016/j.ejogrb.2026.115436
  18. Evolving Fetal Biometry in Fetal Intrahepatic Portosystemic Shunt With Late-Onset Preeclampsia and Focal Umbilical Cord Hypercoiling: A Case Report. — Liu S, Shen X, Tang Y The journal of obstetrics and gynaecology research, 2026, case report · DOI: 10.1111/jog.70526
  19. Research On Advanced Diagnostics and Management of All Pregnancies to Prevent Stillbirth (ROADMAPS) RTI International, 2026, cohort
  20. Predictors for intrapartum cesarean delivery after labor induction for suspected fetal growth restriction at term. — Anteby M, Reichman Y, Bar-Or A et al. International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics, 2026 · DOI: 10.1002/ijgo.71011
  21. Rates of Fetal Growth Restriction and Small for Gestational Age Neonates by COVID-19 Epochs: Did the Pandemic Affect Fetal Biometry Measurements? — Stortz S, Culhane J, Lundsberg L et al. American journal of perinatology, 2026 · DOI: 10.1055/a-2848-3436
  22. Epigenetic Regulation of Aging and its Rejuvenation — Yongpan An, Qian Wang, Ke Gao et al. MedComm, 2025, unknown, 37 citations · DOI: 10.1002/mco2.70369
  23. Human placentation: foundations and implications for reproductive endocrinology and infertility — Elakkiya Prabaharan, David Randall Armant, Sascha Drewlo Systems Biology in Reproductive Medicine, 2025, unknown, 10 citations · DOI: 10.1080/19396368.2025.2533992
  24. High-Risk Outcomes in In Vitro Fertilization Pregnancies for Women of a Very Advanced Maternal Age: Insights from a Multi-Hospital Study in Greece — Themistoklis Loukopoulos, Athanasios Zikopoulos, Efstratios Michaelis Kolibianakis et al. Journal of Clinical Medicine, 2025, case series, 4 citations · DOI: 10.3390/jcm14041323
  25. Placental lesions in small for gestational age fetuses with and without clinical features of fetal growth restriction: a secondary analysis of the Doppler Ratio In fetal Growth restriction Intervention Trial At (near) Term (DRIGITAT) study. — Marijnen MC, van der Meeren LE, Schoots MH et al. American journal of obstetrics and gynecology, 2025, rct, 2 citations · DOI: 10.1016/j.ajog.2025.05.022
  26. [Fetal growth restriction as the disease of the placenta]. — Gérecz B, Belics Z, Molnár G et al. Orvosi hetilap, 2025, unknown, 2 citations · DOI: 10.1556/650.2025.33254
  27. Loss of the maternal effect gene NLRP2 impairs embryonic and extra-embryonic development, revealing a novel genetic cause of congenital anomalies — Momal Sharif, Zahra Anvar, Imen Chakchouk et al. Biology of Reproduction, 2025, animal, 1 citations · DOI: 10.1093/biolre/ioaf290
  28. Pregnancy outcomes in women with different endometriosis lesion types: A review of current evidence. — Munshi H, Barada N, Anand S et al. The journal of obstetrics and gynaecology research, 2025, systematic review, 1 citations · DOI: 10.1111/jog.16321
  29. Predictive value of fetal Doppler velocimetry, fetal growth trajectory and maternal serum biomarkers for short-term adverse perinatal outcome: secondary analysis of DRIGITAT study. — Kamphof HD, Marijnen MC, Damhuis SE et al. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2025, cohort, 1 citations · DOI: 10.1002/uog.29266
  30. Enhancing Management Algorithms for Children Conceived Via Assisted Reproductive Technologies Kazakhstan's Medical University "KSPH", 2025, cohort
  31. Cardiovascular Research in EMbarazo and MAternity (EMMA). Study on Heart Rate Variability and Hemodynamic Adaptations During Pregnancy and Postpartum. Fundacin Biomedica Galicia Sur, 2025, cohort
  32. Association Between First‐Trimester Medication Exposure in Pregnancy and Congenital Anomalies: A Scoping Review of Cohorts, Exposure, Trimester and Congenital Anomaly Definitions — Stephanie Tan, Ebony Quintrell, Shannon Morgan et al. Pharmacoepidemiology and Drug Safety, 2025 · DOI: 10.1002/pds.70293
  33. Differential Effects of Assisted Reproduction Technology on Placental Epigenetics and Angiogenesis: Insights from Fresh, Frozen, and Egg Donation Pregnancies — Anna Maria Nuzzo, Stefano Canosa, Laura Moretti et al. Life, 2025 · DOI: 10.3390/life15121882
  34. Melatonin supplementation attenuates cuproptosis and ferroptosis in aging cumulus and granulosa cells: potential for improving IVF outcomes in advanced maternal age — Kuan‐Hao Tsui, Chia‐Jung Li, Li‐Te Lin Reproductive Biology and Endocrinology, 2024, cohort, 34 citations · DOI: 10.1186/s12958-024-01311-w
  35. Maternal Age at Menarche Genes Determines Fetal Growth Restriction Risk — Решетников Евгений Александрович, Maria Churnosova, Yuliya Reshetnikova et al. International Journal of Molecular Sciences, 2024, 14 citations · DOI: 10.3390/ijms25052647
  36. The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 years — Su Jin You, Danbee Kang, Ji‐Hee Sung et al. Obstetrics & Gynecology Science, 2024, 12 citations · DOI: 10.5468/ogs.24005
  37. The Population-Attributable Fractions of Small-for-Gestational-Age Births: Results from the Japan Birth Cohort Consortium. — Ishitsuka K, Piedvache A, Kobayashi S et al. Nutrients, 2024, meta analysis, 7 citations · DOI: 10.3390/nu16020186
  38. GEN1 as a risk factor for human congenital anomalies of the kidney and urinary tract — Xuanjin Du, Chunyan Wang, Jialu Liu et al. Human Genomics, 2024, 6 citations · DOI: 10.1186/s40246-024-00606-8
  39. Maternal Risk Factors and Perinatal Outcome of Fetal Growth Restriction — Sanyukta Rajbhandary, Suvana Maskey Journal of Nepal Health Research Council, 2024, 2 citations · DOI: 10.33314/jnhrc.v22i03.5175
  40. Antenatal Fetal Surveillance — Umana OD, Vadakekut ES, Siccardi MA StatPearls Publishing, Treasure Island (FL), 2024, 1 citations
  41. Fetal Growth Restriction — Chew LC, Osuchukwu OO, Reed DJ et al. StatPearls Publishing, Treasure Island (FL), 2024, 1 citations
  42. Low maternal plasma apelin in the second trimester is associated with adverse pregnancy outcome in severe, early-onset fetal growth restriction — Braun N, Bethell K, Chaloner L et al. bioRxiv, 2024, unknown, 1 citations · DOI: 10.1101/2024.09.19.613895
  43. Validation of the MaiRa Preeclampsia Test for Screening Early/Late Preeclampsia in First and Second Trimesters iPremom, 2024, cohort
  44. The efficacy of sildenafil therapy in dismal prognosis early-onset intrauterine growth restriction: the STRIDER RCT — Sharp A, Cornforth C, Jackson R et al. National Institute for Health and Care Research, Southampton (UK), 2024
  45. Role of Inflammatory Markers and Doppler Parameters in Late-Onset Fetal Growth Restriction: A Machine Learning Approach Ankara Etlik City Hospital, 2024, cohort
  46. THE PROBLEM OF POPULATION AGING AND THE INCREASING INCIDENCE OF ACHONDROPLASIA AND OTHER CONGENITAL ANOMALIES IN OFFSPRING — Хальчицкий Сергей Егорович, Konstantin G. Buslov, Marina Vanikovna Sogoyan 2024 · DOI: 10.34660/inf.2024.69.83.094
  47. The updated understanding of advanced maternal age — Xuan Ye, Philip Newton Baker, Chao Tong Fundamental Research, 2023, systematic review, 41 citations · DOI: 10.1016/j.fmre.2023.09.013
  48. Maternal PlGF and umbilical Dopplers predict pregnancy outcomes at diagnosis of early-onset fetal growth restriction — Rebecca N. Spencer, Kasia Maksym, Kurt Hecher et al. Journal of Clinical Investigation, 2023, cohort, 32 citations · DOI: 10.1172/jci169199
  49. The inter- and multi- generational epigenetic alterations induced by maternal cadmium exposure — Lauren Lawless, Linglin Xie, Ke Zhang Frontiers in Cell and Developmental Biology, 2023, systematic review, 22 citations · DOI: 10.3389/fcell.2023.1148906
  50. Maternal age is highly associated with non‐chromosomal congenital anomalies: Analysis of a population‐based case‐control database — Boglárka Pethő, Ákos Mátrai, Gergely Agócs et al. BJOG An International Journal of Obstetrics & Gynaecology, 2023, 20 citations · DOI: 10.1111/1471-0528.17461
  51. A systematic review of in utero cannabis exposure and risk for structural birth defects — Ayesha C. Sujan, Anish Pal, Lyndsay Ammon Avalos et al. Frontiers in Pediatrics, 2023, systematic review, 18 citations · DOI: 10.3389/fped.2023.1149401
  52. Maternal plasma syndecan-1: a biomarker for fetal growth restriction — Alexander L. Juusela, Eunjung Jung, Dahiana Marcela Gallo et al. The Journal of Maternal-Fetal & Neonatal Medicine, 2023, 7 citations · DOI: 10.1080/14767058.2022.2150074
  53. Epidemiology of birth defects in a national hospital-based birth defect surveillance spot in Southern Jiangsu, China, 2014–2018 — Ying Zhou, Di Yang, Xueqin Mao et al. Frontiers in Medicine, 2023, 3 citations · DOI: 10.3389/fmed.2023.1138946
  54. Pattern of Congenital Malformations at Birth and Their Associated Maternal Characteristics — Sahar Hassan, Nassrin Malik Aubead Journal of Obstetrics Gynecology and Cancer Research, 2023, 2 citations · DOI: 10.30699/jogcr.8.3.255
  55. Fetal, Obstetrics and Reproduction Genomics Fundación Ginemed, 2023, cohort
  56. Paternal Age and Fetal Aneuploidy Clinique Ovo, 2023, cohort
  57. Clinical Opinion: The diagnosis and management of suspected fetal growth restriction: an evidence-based approach. — Lees CC, Romero R, Stampalija T et al. American journal of obstetrics and gynecology, 2022, expert opinion, 154 citations · DOI: 10.1016/j.ajog.2021.11.1357
  58. Congenital anomalies and maternal age: A systematic review and meta‐analysis of observational studies — Damin Ahn, Jieon Kim, Junyeong Kang et al. Acta Obstetricia Et Gynecologica Scandinavica, 2022, systematic review, 84 citations · DOI: 10.1111/aogs.14339
  59. Placental Dysfunction in Assisted Reproductive Pregnancies: Perinatal, Neonatal and Adult Life Outcomes — Claudio Manna, Valentina Lacconi, Giuseppe Rizzo et al. International Journal of Molecular Sciences, 2022, unknown, 62 citations · DOI: 10.3390/ijms23020659
  60. Contemporary Use of ICSI and Epigenetic Risks to Future Generations. — Sciorio R, Esteves SC Journal of clinical medicine, 2022, systematic review, 28 citations · DOI: 10.3390/jcm11082135
  61. Advanced Maternal Age Differentially Affects Embryonic Tissues with the Most Severe Impact on the Developing Brain — Caroline Kokorudz, Bethany N. Radford, Wendy Dean et al. Cells, 2022, 14 citations · DOI: 10.3390/cells12010076
  62. Assisted Reproductive Technology Treatment, the Catalyst to Amplify the Effect of Maternal Infertility on Preterm Birth — Youzhen Zhang, Wei Zhou, Wanbing Feng et al. Frontiers in Endocrinology, 2022, 11 citations · DOI: 10.3389/fendo.2022.791229
  63. Risk factors and adverse pregnancy outcomes in older pregnant women with hypertensive disorders of pregnancy. — Zhang H, Wang W The journal of obstetrics and gynaecology research, 2022, meta analysis, 5 citations · DOI: 10.1111/jog.15295
  64. Fetal biometry is assessment of fetal growth restriction in Telangana region — Upendhar Reddy Pulluru, Sudhakara Babu Chelli, Poojitha MakiReddy et al. International Journal of Health Sciences, 2022, 1 citations · DOI: 10.53730/ijhs.v6ns6.10030
  65. Association of maternal age and development of congenital malformations — DR. Prabhuswami Hiremath , DR (Mrs) Lekshmi Sudhish Nair , DR Vaishali R Mohite , DR Jyoti Salunkhe , DR. Prakash Naregal , Mrs. Afsana Mulani , Mr. shrikant Desai Journal of Pharmaceutical Negative Results, 2022 · DOI: 10.47750/pnr.2022.13.s07.720
  66. Epigenetic Alterations of Maternal Tobacco Smoking during Pregnancy: A Narrative Review — Aurélie Nakamura, Olivier François, Johanna Lepeule International Journal of Environmental Research and Public Health, 2021, systematic review, 77 citations · DOI: 10.3390/ijerph18105083
  67. Fetal interventions for congenital renal anomalies — Ahmer Irfan, Elizabeth O’Hare, Eric Bradley Jelin Translational Pediatrics, 2021, 16 citations · DOI: 10.21037/tp-2020-fs-05
  68. Race and ethnicity are among the predisposing factors for fetal malpresentation at term. — Bar-El L, Eliner Y, Grunebaum A et al. American journal of obstetrics & gynecology MFM, 2021 · DOI: 10.1016/j.ajogmf.2021.100405
  69. Vitamin D-Binding Protein in Pregnancy and Reproductive Health — Melinda Fernando, Stacey J. Ellery, Clara Marquina et al. Nutrients, 2020, unknown, 98 citations · DOI: 10.3390/nu12051489
  70. The Effects of Parent Ages on Birth Defects — James Alan Thompson Acta Scientific Paediatrics, 2020, 4 citations · DOI: 10.31080/aspe.2020.03.0312
  71. ISUOG Practice Guidelines: ultrasound assessment of fetal biometry and growth. — Salomon LJ, Alfirevic Z, Da Silva Costa F et al. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2019, guideline, 697 citations · DOI: 10.1002/uog.20272
  72. Neonatal Morbidities of Fetal Growth Restriction: Pathophysiology and Impact — Anil K. Malhotra, Beth J. Allison, Margie Castillo-Meléndez et al. Frontiers in Endocrinology, 2019, unknown, 451 citations · DOI: 10.3389/fendo.2019.00055
  73. Effectiveness of routine third trimester ultrasonography to reduce adverse perinatal outcomes in low risk pregnancy (the IRIS study): nationwide, pragmatic, multicentre, stepped wedge cluster randomised trial. — Henrichs J, Verfaille V, Jellema P et al. BMJ (Clinical research ed.), 2019, rct, 81 citations · DOI: 10.1136/bmj.l5517
  74. Advanced maternal age compromises fetal growth and induces sex-specific changes in placental phenotype in rats — Tina Napso, Yin-Po Hung, Sandra Thomas Davidge et al. Scientific Reports, 2019, animal, 63 citations · DOI: 10.1038/s41598-019-53199-x
  75. Validation of a NICS Method Using the Culture Medium Instituto Bernabeu, 2019, cohort
  76. Correlation of Maternal Age with Prevalence of Chromosomal Anomalies in Patients of Anorectal Malformation — Dewanshi Mishra, Rakesh Kumar Verma, Archana Rani et al. Academia Anatomica International, 2019 · DOI: 10.21276/aanat.2019.5.1.21
  77. Diagnosis and surveillance of late-onset fetal growth restriction. — Figueras F, Caradeux J, Crispi F et al. American journal of obstetrics and gynecology, 2018, expert opinion, 188 citations · DOI: 10.1016/j.ajog.2017.12.003
  78. The World Health Organization fetal growth charts: concept, findings, interpretation, and application. — Kiserud T, Benachi A, Hecher K et al. American journal of obstetrics and gynecology, 2018, cohort, 159 citations · DOI: 10.1016/j.ajog.2017.12.010
  79. Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial. — Sharp A, Cornforth C, Jackson R et al. The Lancet. Child & adolescent health, 2018, rct, 146 citations · DOI: 10.1016/s2352-4642(17)30173-6
  80. The role of aspirin, heparin, and other interventions in the prevention and treatment of fetal growth restriction. — Groom KM, David AL American journal of obstetrics and gynecology, 2018, meta analysis, 124 citations · DOI: 10.1016/j.ajog.2017.11.565
  81. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. — Gaccioli F, Aye ILMH, Sovio U et al. American journal of obstetrics and gynecology, 2018, unknown, 108 citations · DOI: 10.1016/j.ajog.2017.12.002
  82. Screening for fetal growth restriction using ultrasound and the sFLT1/PlGF ratio in nulliparous women: a prospective cohort study. — Gaccioli F, Sovio U, Cook E et al. The Lancet. Child & adolescent health, 2018, cohort, 106 citations · DOI: 10.1016/s2352-4642(18)30129-9
  83. The Effect of Very Advanced Maternal Age on Maternal and Neonatal Outcomes: A Systematic Review. — Leader J, Bajwa A, Lanes A et al. Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC, 2018, systematic review, 56 citations · DOI: 10.1016/j.jogc.2017.10.027
  84. Maternal hemodynamics, fetal biometry and Doppler indices in pregnancies followed up for suspected fetal growth restriction — Lewis Roberts, Hua Zen Ling, Liona C. Poon et al. Ultrasound in Obstetrics and Gynecology, 2018, cohort, 50 citations · DOI: 10.1002/uog.19067
  85. Advanced maternal age and adverse pregnancy outcomes: A systematic review and meta-analysis. — Lean SC, Derricott H, Jones RL et al. PloS one, 2017, meta analysis, 733 citations · DOI: 10.1371/journal.pone.0186287
  86. Placental Dysfunction Underlies Increased Risk of Fetal Growth Restriction and Stillbirth in Advanced Maternal Age Women — Samantha C. Lean, Alexander E. P. Heazell, Mark Dilworth et al. Scientific Reports, 2017, cohort, 155 citations · DOI: 10.1038/s41598-017-09814-w
  87. Early onset fetal growth restriction — A. Dall’Asta, Valentina Brunelli, Federico Prefumo et al. Maternal Health Neonatology and Perinatology, 2017, unknown, 109 citations · DOI: 10.1186/s40748-016-0041-x
  88. EVERREST prospective study: a 6-year prospective study to define the clinical and biological characteristics of pregnancies affected by severe early onset fetal growth restriction. — Spencer R, Ambler G, Brodszki J et al. BMC pregnancy and childbirth, 2017, cohort, 65 citations · DOI: 10.1186/s12884-017-1226-7
  89. Advanced Maternal Age and Incidence of Non-Chromosomal Congenital Anomalies: A Population-based Study [35Q] — Matt Grossi, Susan Crawford, Sue Chandra Obstetrics and Gynecology, 2017, 4 citations · DOI: 10.1097/01.aog.0000514144.08234.ef
  90. Abnormal umbilical artery Doppler velocimetry and placental histopathological correlation in fetal growth restriction — Rachna Agarwal, Arushi Tiwari, Neelam Wadhwa et al. South African Journal of Obstetrics and Gynaecology, 2017, 3 citations · DOI: 10.7196/sajog.2017.v23i1.1109
  91. Consensus definition of fetal growth restriction: a Delphi procedure — Sanne Jehanne Gordijn, Irene Maria Beune, B. Thilaganathan et al. Ultrasound in Obstetrics and Gynecology, 2016, expert opinion, 1630 citations · DOI: 10.1002/uog.15884
  92. Congenital anomalies: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data — Malini B. DeSilva, Flor M. Muñoz, Mark McMillan et al. Vaccine, 2016, unknown, 160 citations · DOI: 10.1016/j.vaccine.2016.03.047
  93. Programming of maternal and offspring disease: impact of growth restriction, fetal sex and transmission across generations — Jean N. Cheong, Mary E. Wlodek, Karen M. Moritz et al. The Journal of Physiology, 2016, unknown, 147 citations · DOI: 10.1113/jp271745
  94. Advanced Maternal Age and Offspring Outcomes: Reproductive Aging and Counterbalancing Period Trends — Kieron James Barclay, Mikko Myrskylä Population and Development Review, 2016, unknown, 146 citations · DOI: 10.1111/j.1728-4457.2016.00105.x
  95. Epidemiology of Birth Defects Based on a Birth Defect Surveillance System from 2005 to 2014 in Hunan Province, China — Donghua Xie, Tubao Yang, Zhiyu Liu et al. PLoS ONE, 2016, cross sectional, 84 citations · DOI: 10.1371/journal.pone.0147280
  96. Expression of epigenetic machinery genes is sensitive to maternal obesity and weight loss in relation to fetal growth in mice — Polina E. Panchenko, Sarah Amandine Caroline Voisin, Mélanie Jouin et al. Clinical Epigenetics, 2016, animal, 76 citations · DOI: 10.1186/s13148-016-0188-3
  97. Fetal growth restriction and intra-uterine growth restriction: guidelines for clinical practice from the French College of Gynaecologists and Obstetricians. — Vayssière C, Sentilhes L, Ego A et al. European journal of obstetrics, gynecology, and reproductive biology, 2015, guideline, 178 citations · DOI: 10.1016/j.ejogrb.2015.06.021
  98. Advanced maternal age, pregnancy and birth — Reeta Lamminpää UEF eRepo (University of Eastern Finland), 2015, 6 citations
  99. Epigenetic mechanisms of hypoxic preconditioning — Elena A. Rybnikova, М. О. Самойлов SpringerPlus, 2015, 1 citations · DOI: 10.1186/2193-1801-4-s1-l39
  100. The Correlation Between Maternal Diabetes and Birth Defects — Erin Stanton Digital Commons (Liberty University), 2015
  101. A Study to Determine the Safety and Efficacy of the RSV F Vaccine to Protect Infants Via Maternal Immunization Novavax, 2015, rct
  102. The influence of maternal prenatal and early childhood nutrition and maternal prenatal stress on offspring immune system development and neurodevelopmental disorders — Andrea Horvath Marques, Thomas G. O’Connor, Christine Roth et al. Frontiers in Neuroscience, 2013, unknown, 225 citations · DOI: 10.3389/fnins.2013.00120
  103. Epigenetics of gestational diabetes mellitus and offspring health: the time for action is in early stages of life — H Lehnen, Ulrich Zechner, Thomas Haaf Molecular Human Reproduction, 2013, unknown, 140 citations · DOI: 10.1093/molehr/gat020
  104. Maternal Smoking During Pregnancy and Fetal Biometry — Carmen Íñiguez, Ferrán Ballester, Olga Costa et al. American Journal of Epidemiology, 2013, 41 citations · DOI: 10.1093/aje/kwt085
  105. Maternal age and birth defects after the use of assisted reproductive technology in Japan, 2004–2010 — Syuichi Ooki International Journal of Women s Health, 2013, 19 citations · DOI: 10.2147/ijwh.s32296
  106. Maternal Cardiovascular Impairment in Pregnancies Complicated by Severe Fetal Growth Restriction — Karen Melchiorre, George Ross Sutherland, Marco Liberati et al. Hypertension, 2012, case control, 113 citations · DOI: 10.1161/hypertensionaha.112.194159
  107. Predictors of poor perinatal outcome following maternal perception of reduced fetal movements--a prospective cohort study. — Dutton PJ, Warrander LK, Roberts SA et al. PloS one, 2012, cohort, 98 citations · DOI: 10.1371/journal.pone.0039784
  108. Ultrasound Evidence of Early Fetal Growth Restriction after Maternal Malaria Infection — Marcus J. Rijken, Aris T. Papageorghiou, Supan Thiptharakun et al. PLoS ONE, 2012, cohort, 80 citations · DOI: 10.1371/journal.pone.0031411
  109. The Results of Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening of Embryos Obtained From GnRH-agonist Long and GnRH-antagonist Ovarian Stimulation Protocol European Hospital, 2012, rct
  110. Diagnosis and Management of Fetal Growth Restriction — Jacqueline E. A. K. Bamfo, Anthony O. Odibo Journal of Pregnancy, 2011, unknown, 178 citations · DOI: 10.1155/2011/640715
  111. Advanced paternal age and reproductive outcome — Zofnat Wiener‐Megnazi, Ron Auslender, Martha Dirnfeld Asian Journal of Andrology, 2011, unknown, 111 citations · DOI: 10.1038/aja.2011.69
  112. Maternal progesterone level in fetal growth restriction and its relationship with Doppler velocimetry indices. — Sedigheh Borna, Mahin Bandarian, Mohammad Reza Abdollahi et al. PubMed, 2011, 5 citations
  113. Maternal Occupational Exposure to Organic Solvents and Congenital Malformations — Ronan Garlantézec, Sylvaine Cordier theses.fr (ABES), 2011
  114. Epigenetics meets endocrinology — Xiang Zhang, Shuk‐Mei Ho Journal of Molecular Endocrinology, 2010, expert opinion, 298 citations · DOI: 10.1677/jme-10-0053
  115. Gene expression in the placenta: maternal stress and epigenetic responses — Ciprian Paul Gheorghe, Ravi Goyal, Ashwani Mittal et al. The International Journal of Developmental Biology, 2009, unknown, 153 citations · DOI: 10.1387/ijdb.082770cg
  116. A current genetic and epigenetic view on human aging mechanisms. — Sala Ostojić, Nina Pereza, Miljenko Kapović PubMed, 2009, 14 citations
  117. Protein restriction during gestation and/or lactation causes adverse transgenerational effects on biometry and glucose metabolism in F1 and F2 progenies of rats. — Pinheiro AR, Salvucci ID, Aguila MB et al. Clinical science (London, England : 1979), 2008, animal, 97 citations · DOI: 10.1042/cs20070302
  118. Prenatal Cytogenetic Diagnosis by Array-Based Copy Number Analysis Columbia University, 2008, cohort
  119. Screening for pre-eclampsia and fetal growth restriction by uterine artery Doppler and PAPP-A at 11-14 weeks' gestation. — Pilalis A, Souka AP, Antsaklis P et al. Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 2007, cohort, 118 citations · DOI: 10.1002/uog.3881
  120. Optimising perinatal outcome in fetal growth restriction using doppler velocimetry — Soundarapandian Sunitha 2007
  121. Association of paternal age with prevalence of selected birth defects — Natalie P. Archer, Peter H. Langlois, Lucina Suarez et al. Birth Defects Research Part A Clinical and Molecular Teratology, 2006, 70 citations · DOI: 10.1002/bdra.20316
  122. Turner Syndrome Prenatal Diagnosis Study Seattle Children's Hospital, 2006, cohort
  123. Paternal age and congenital malformations — Jin Liang Zhu, Kreesten Meldgaard Madsen, Mogens Vestergaard et al. Human Reproduction, 2005, cohort, 138 citations · DOI: 10.1093/humrep/dei186
  124. First-trimester screening for fetal triploidy at 11 to 14 weeks: a role for fetal biometry — Laurent Julien Salomon, J. P. Bernard, J. Nizard et al. Prenatal Diagnosis, 2005, 89 citations · DOI: 10.1002/pd.1170
  125. Fetal age assessment based on ultrasound head biometry and the effect of maternal and fetal factors — Synnøve Lian Johnsen, Svein Rasmussen, Rita Sollien et al. Acta Obstetricia Et Gynecologica Scandinavica, 2004, 95 citations · DOI: 10.1080/j.0001-6349.2004.00485.x
  126. Integrated fetal testing in growth restriction: combining multivessel Doppler and biophysical parameters — Ahmet Baschat Ultrasound in Obstetrics and Gynecology, 2003, 104 citations · DOI: 10.1002/uog.21
  127. Intrauterine growth restriction is accompanied by decreased renal volume in the human fetus. — Silver LE, Decamps PJ, Korst LM et al. American journal of obstetrics and gynecology, 2003, 99 citations · DOI: 10.1067/mob.2003.270
  128. Cell-free fetal DNA concentration in plasma of patients with abnormal uterine artery Doppler waveform and intrauterine growth restriction--a pilot study. — Caramelli E, Rizzo N, Concu M et al. Prenatal diagnosis, 2003, 65 citations · DOI: 10.1002/pd.596
  129. Maternal serum activin A levels in association with intrauterine fetal growth restriction — Euan Morrison Wallace, Michal Elisabeth Schneider, Andrew Edwards et al. BJOG An International Journal of Obstetrics & Gynaecology, 2003, 36 citations · DOI: 10.1016/s1470-0328(02)02990-7
  130. Congenital malformations in 4224 children conceived after IVF — S. Anthony Human Reproduction, 2002, cohort, 156 citations · DOI: 10.1093/humrep/17.8.2089
  131. Prognostic role of umbilical artery Doppler velocimetry in growth-restricted fetuses — Mirella Soregaroli, R. Bonera, Luana Danti et al. The Journal of Maternal-Fetal & Neonatal Medicine, 2002, 90 citations · DOI: 10.1080/713605482
  132. Prognostic role of umbilical artery Doppler velocimetry in growth-restricted fetuses. — Soregaroli M, Bonera R, Danti L et al. The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians, 2002, 55 citations · DOI: 10.1080/jmf.11.3.199.203
  133. Fetal Doppler velocimetry at high altitude — Elisabeth Krampl, Christoph C. Lees, J Martin Bland et al. Ultrasound in Obstetrics and Gynecology, 2001, 31 citations · DOI: 10.1046/j.0960-7692.2001.00542.x
  134. Relationship between arterial and venous Doppler and perinatal outcome in fetal growth restriction — Ahmet Baschat, Ulrich Gembruch, Irwin K. M. Reiss et al. Ultrasound in Obstetrics and Gynecology, 2000, cohort, 286 citations · DOI: 10.1046/j.1469-0705.2000.00284.x
  135. Maternal concentrations and fetal-maternal concentration differences of plasma amino acids in normal and intrauterine growth-restricted pregnancies. — Cetin I, Ronzoni S, Marconi AM et al. American journal of obstetrics and gynecology, 1996, 127 citations · DOI: 10.1016/s0002-9378(96)70609-9
  136. The association between an abnormal nuchal skin fold, trisomy 21, and ultrasound abnormalities identified during the second trimester of pregnancy. — DeVore GR, Alfi O Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology, 1993, 16 citations · DOI: 10.1046/j.1469-0705.1993.03060387.x